GlassScriptPhysician profile
Annapurna Devi Korimilli
NPI 1053556167
$1,754.36
in general payments reported to CMS, 2019-2025
19 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $307 · 2021: $302 · 2024: $34.51 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.31 | 2019-2021 | |
| Pfizer INC. | $230.77 | 2019-2025 | |
| Janssen Biotech, INC. | $181.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.08 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $94.61 | 2019-2020 | |
| Shionogi INC | $86.50 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $45.75 | 2019 | |
| Medtronic, INC. | $34.51 | 2024 | Gi Genius |
| Merck Sharp & Dohme LLC | $27.11 | 2020-2021 | |
| Celltrion USA INC. | $27.00 | 2025 | Vegzelma |
| Amgen INC. | $26.41 | 2021 | |
| Allergan, INC. | $25.03 | 2019 | |
| Celgene Corporation | $18.25 | 2021 | |
| Ucb, INC. | $16.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $13.15 | 2019 | |
| Braintree Laboratories, INC. | $12.33 | 2019 | |
| Novo Nordisk INC | $12.08 | 2020 | |
| Concordia Pharmaceuticals INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annapurna Korimilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.